Source comparison
ARA-290 vs BPC-157 — Which Peptide for Recovery?
Clinical peptide research has exploded over the past decade, with hundreds of novel compounds entering preclinical and early-phase trials. Two peptides have emerged as particularly promising for tissue protection and repair: ARA-290 and BPC-157. Both show rema
This comparison does not assign a generated winner or score.
- Clinical peptide research has exploded over the past decade, with hundreds of novel compounds entering preclinical and early-phase trials. Two peptides have emerged as particularly promising for tissue protection and repair: ARA-290 and BPC-157. Both show remarkable regenerative potential in animal models, but their mechanisms of action, clinical applications, and evidence bases differ substantially. Choosing between them requires understanding exactly what each compound does at the cellular level. And what it doesn't.
- We've worked with researchers exploring both compounds across dozens of study protocols. The confusion around ARA-290 vs BPC-157 usually stems from one misconception: that all healing peptides work through the same pathway. They don't. One protects tissue by activating innate repair receptors; the other accelerates healing by directly stimulating angiogenesis and collagen synthesis.
- What is the difference between ARA-290 vs BPC-157?
- ARA-290 is a selective agonist of the innate repair receptor (IRR), triggering tissue-protective pathways primarily in neural and endothelial tissue. BPC-157 is a synthetic pentadecapeptide derived from gastric protective protein BPC, promoting angiogenesis, collagen formation, and musculoskeletal repair through growth factor modulation. The two compounds target fundamentally different biological systems.
- Both peptides demonstrate tissue-protective and regenerative effects in preclinical models, but their therapeutic targets diverge substantially. ARA-290 shows strongest evidence for neuroprotection, diabetic neuropathy, and inflammatory conditions where tissue-protective signaling is impaired. BPC-157 demonstrates consistent efficacy in musculoskeletal injury models. Ligament tears, tendon damage, muscle strains. Where accelerated healing and vascular growth are the primary therapeutic goals. Understanding which pathway your research question requires is the first decision point.